[Clinical research activity of the French cancer cooperative network: Overview and perspectives].

Introduction: The French Cancer Plan 2014-2019 stresses the importance of strengthening collaboration between all stakeholders involved in the fight against cancer, including cancer cooperative groups and intergroups. This survey aimed to describe the basics characteristics and clinical research activity among the Cancer Cooperative Groups (Groupes coopérateurs en oncologie). The second objective was to identify facilitators and barriers to their research activity.

Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (Permixon(R)) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

This prospective, controlled study was undertaken to evaluate the early urodynamic and symptomatic impact of the lipido-sterolic extract of Serenoa repens (Permixon(R) ) in the treatment of patients with benign prostatic hyperplasia (BPH). A total of 75 patients, aged 52-78 y with lower urinary tract symptoms due to mild/moderate BPH (mean International Prostate Symptom Score (I-PSS) 8.2) were included in the study, of which 57 received Permixon(R) 160 mg twice daily for 9 weeks.

Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study.

Objective: Benign prostatic hyperplasia (BPH) and its treatment can impair the quality of life (QoL) of patients with the condition. Among the BPH-specific instruments available for assessing QoL, no consensus has emerged on the concepts that should be measured, particularly for aspects of sexual life. The objective of this study was to determine which aspects of QoL were most affected by prostatic symptoms and which patients considered the most important.